Substance / Medication

Infigratinib

Overview

Active Ingredient
infigratinib
RxNorm CUI
2550729

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Oral Infigratinib Therapy in Children with Achondroplasia.
Savarirayan Ravi, De Bergua Josep Maria, Arundel Paul et al. · N Engl J Med · 2025
PMID: 39555818Observational
Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
Botrus Gehan, Raman Puneet, Oliver Thomas et al. · Expert Opin Investig Drugs · 2021
PMID: 33307867Observational
Infigratinib is a weak inhibitor of the FGFR3-N540K mutant associated with hypochondroplasia.
Ursachi Vlad-Constantin, Feketova Zuzana, Czyrek Aleksandra Anna et al. · J Bone Miner Res · 2026
PMID: 41582902Other
Response to Letter to the Editor for "Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia".
Legeai-Mallet Laurence, Shah Bhavik · J Bone Miner Res · 2026
PMID: 41593746Other
Oral Infigratinib in Children with Achondroplasia - Targeted Treatment.
Hoyer-Kuhn Heike · N Engl J Med · 2025
PMID: 40009811Other
Oral Infigratinib Therapy in Children with Achondroplasia.
Rico-Llanos Gustavo, Czyrek Aleksandra A, Krejci Pavel · N Engl J Med · 2025
PMID: 40532160Other
Oral Infigratinib Therapy in Children with Achondroplasia. Reply.
Savarirayan Ravi, Rogoff Daniela · N Engl J Med · 2025
PMID: 40532161Other
Combined inhibition of EGFR and FGFRs with Cetuximab and Infigratinib showed effectiveness and relevance in proliferation and migration of HNSCC cell lines.
Orsolic Monika, Diensthuber Marc, Stöver Timo et al. · Biochim Biophys Acta Mol Basis Dis · 2025
PMID: 40449758Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Infigratinib (substance)
SNOMED CT
1162483003
UMLS CUI
C3254591
RxNorm CUI
2550729

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.